JPS6341888B2 - - Google Patents
Info
- Publication number
- JPS6341888B2 JPS6341888B2 JP54101210A JP10121079A JPS6341888B2 JP S6341888 B2 JPS6341888 B2 JP S6341888B2 JP 54101210 A JP54101210 A JP 54101210A JP 10121079 A JP10121079 A JP 10121079A JP S6341888 B2 JPS6341888 B2 JP S6341888B2
- Authority
- JP
- Japan
- Prior art keywords
- patients
- immune function
- decline
- dialysis
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000036737 immune function Effects 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 6
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 2
- 229960002535 alfacalcidol Drugs 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 108010023088 staphage lysate Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000009852 uremia Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 medium chain fatty acid triglycerides Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10121079A JPS5626819A (en) | 1979-08-10 | 1979-08-10 | Preventive for hypoimmunity |
| US06/176,641 US4340604A (en) | 1979-08-10 | 1980-08-11 | Method for inhibiting the lowering of immunological function and agent therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10121079A JPS5626819A (en) | 1979-08-10 | 1979-08-10 | Preventive for hypoimmunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5626819A JPS5626819A (en) | 1981-03-16 |
| JPS6341888B2 true JPS6341888B2 (enExample) | 1988-08-19 |
Family
ID=14294548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10121079A Granted JPS5626819A (en) | 1979-08-10 | 1979-08-10 | Preventive for hypoimmunity |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4340604A (enExample) |
| JP (1) | JPS5626819A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6045516A (ja) * | 1983-08-02 | 1985-03-12 | Kureha Chem Ind Co Ltd | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 |
| US4749710A (en) * | 1985-05-01 | 1988-06-07 | Hoffmann-La Roche Inc. | Immunosuppressive agents |
| US4997824A (en) * | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| US6291444B1 (en) | 1993-06-16 | 2001-09-18 | Wisconsin Alumni Research Foundation | Treatment of t-cell immunodeficiencies with vitamin D compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3741996A (en) * | 1971-12-02 | 1973-06-26 | Wisconsin Alumni Res Found | 1{60 -hydroxycholecalciferol |
| JPS603045B2 (ja) * | 1976-04-19 | 1985-01-25 | 中外製薬株式会社 | １α―ヒドロキシビタミンＤ類軟カプセルの製造方法 |
| US4225525A (en) * | 1979-02-08 | 1980-09-30 | Hoffmann-La Roche Inc. | Vitamin D3 metabolite derivatives |
-
1979
- 1979-08-10 JP JP10121079A patent/JPS5626819A/ja active Granted
-
1980
- 1980-08-11 US US06/176,641 patent/US4340604A/en not_active Expired - Lifetime
Non-Patent Citations (2)
| Title |
|---|
| ACTA POEDIAT SCAND=1970 * |
| ACTA POEDIAT SCAND=1976 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5626819A (en) | 1981-03-16 |
| US4340604A (en) | 1982-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Craft | Torsade de pointes after astemizole overdose | |
| Jaques et al. | Intrapulmonary heparin: A new procedure for anticoagulant therapy | |
| Bogartz et al. | Pulmonary edema associated with propoxyphene intoxication | |
| Freeman et al. | Plasmapheresis in acute liver failure | |
| Singer et al. | Risks and benefits of home parenteral nutrition in the acquired immunodeficiency syndrome | |
| McCurdy | Chloramphenicol bone marrow toxicity | |
| JPS6365646B2 (enExample) | ||
| Nilsson et al. | Charcoal hemoperfusion for treatment of serious carbamazepine poisoning | |
| Kulig et al. | Levothyroxine overdose associated with seizures in a young child | |
| JPS6341888B2 (enExample) | ||
| Harinasuta et al. | Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria; a double-blind trial for determining the most effective dose | |
| Harrison et al. | Bolus corticosteroids and cyclophosphamide for initial treatment of Wegener's granulomatosis | |
| De Vos et al. | Disseminated lntravascular Coagulation during a Fatal Mycoplasma pneumoniae Infection | |
| Lansing et al. | Angina during hemodialysis: treatment by coronary bypass graft | |
| Kelbaek et al. | Effects of autonomic blockade on cardiac function at rest and during upright exercise in humans | |
| SHANNON et al. | Exchange transfusion in the treatment of severe theophylline poisoning | |
| Steiner | Idiopathic pulmonary haemosiderosis and rheumatoid arthritis | |
| Safar et al. | Central haemodynamics and plasma prostaglandin E2 in borderline and sustained essential hypertensive patients before and after indomethacin | |
| Gosselin et al. | Acute intoxication with diisopyramide: clinical and experimental study by hemoperfusion on amberlite XAD 4 resin | |
| BERLINGER et al. | Hemoperfusion for phenylbutazone poisoning | |
| Sperryn et al. | Double-blind comparison of aspirin and 4-(acetamido) phenyl-2-acetoxy-benzoate (benorylate) in rheumatoid arthritis | |
| Rubinger et al. | Inefficiency of haemodialysis in acute phenytoin intoxication | |
| Williams | Blood doping: An update | |
| Bergström et al. | Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. | |
| US3969525A (en) | Method for reducing the heart beat frequency |